Products - Children and teenagers | Topic

Showing 28 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Multidisciplinary care of children and young people with achondroplasia
Status:
In development
Programme:
NICE review
Expected publication date:
29 April 2026
Epilepsies in children, young people and adults (SeLECTS)
Status:
In development
Programme:
NICE guideline
Expected publication date:
5 August 2026
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 August 2026
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Gender Incongruence Services for Children and Young People
Status:
In development
Expected publication date:
18 February 2027
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
1 July 2026
Expected publication date:
TBC

Children and teenagers Products

Filter

Product type

Guidance programme

Advice programme

Status
1 selected

New and updated

Showing 28 products

Multidisciplinary care of children and young people with achondroplasia

Epilepsies in children, young people and adults (SeLECTS)

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

Gender Incongruence Services for Children and Young People

Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]

School-based interventions: physical and mental health and wellbeing promotion

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]

Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]

Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]

Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713

Children and teenagers Products

Filter

Product type

Guidance programme

Advice programme

Status1 selected

New and updated

Showing 28 products

Status
1 selected